Swedish Orphan Biovitrum マネジメント

マネジメント基準チェック /44

Swedish Orphan Biovitrumの CEO はGuido Oelkersで、 May2017年に任命され、の在任期間は 7.58年です。の年間総報酬はSEK 48.88Mで、 25.1%給与と74.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.12%を直接所有しており、その価値は€ 11.52M 。経営陣と取締役会の平均在任期間はそれぞれ5.9年と4.1年です。

主要情報

Guido Oelkers

最高経営責任者

SEK 48.9m

報酬総額

CEO給与比率	25.1%
CEO在任期間	7.6yrs
CEOの所有権	0.1%
経営陣の平均在職期間	5.9yrs
取締役会の平均在任期間	4.1yrs

経営陣の近況

Recent updates

CEO報酬分析

Swedish Orphan Biovitrum の収益と比較して、Guido Oelkers の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	SEK 4b
Jun 30 2024	n/a	n/a	SEK 2b
Mar 31 2024	n/a	n/a	SEK 2b
Dec 31 2023	SEK 49m	SEK 12m	SEK 2b
Sep 30 2023	n/a	n/a	SEK 3b
Jun 30 2023	n/a	n/a	SEK 3b
Mar 31 2023	n/a	n/a	SEK 3b
Dec 31 2022	SEK 47m	SEK 11m	SEK 3b
Sep 30 2022	n/a	n/a	SEK 2b
Jun 30 2022	n/a	n/a	SEK 3b
Mar 31 2022	n/a	n/a	SEK 3b
Dec 31 2021	SEK 42m	SEK 10m	SEK 3b
Sep 30 2021	n/a	n/a	SEK 3b
Jun 30 2021	n/a	n/a	SEK 3b
Mar 31 2021	n/a	n/a	SEK 3b
Dec 31 2020	SEK 33m	SEK 10m	SEK 3b
Sep 30 2020	n/a	n/a	SEK 3b
Jun 30 2020	n/a	n/a	SEK 3b
Mar 31 2020	n/a	n/a	SEK 4b
Dec 31 2019	SEK 33m	SEK 10m	SEK 3b
Sep 30 2019	n/a	n/a	SEK 3b
Jun 30 2019	n/a	n/a	SEK 3b
Mar 31 2019	n/a	n/a	SEK 3b
Dec 31 2018	SEK 26m	SEK 9m	SEK 2b
Sep 30 2018	n/a	n/a	SEK 2b
Jun 30 2018	n/a	n/a	SEK 2b
Mar 31 2018	n/a	n/a	SEK 1b
Dec 31 2017	SEK 16m	SEK 5m	SEK 1b

報酬と市場: Guidoの総報酬 ($USD 4.41M ) は、 German市場 ($USD 4.84M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Guidoの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Guido Oelkers (59 yo)

7.6yrs

在職期間

SEK 48,883,000

報酬

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Guido Oelkers	CEO & President	7.6yrs	SEK 48.88m	0.12% € 11.5m
Henrik Stenqvist	Chief Financial Officer	6.4yrs	データなし	0.016% € 1.5m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.9yrs	データなし	0.0089% € 822.7k
Daniel Rankin	Head of Strategy & Corporate Development	2.9yrs	データなし	0.0029% € 265.0k
Lena Bjurner	Head of Human Resources	1.9yrs	データなし	データなし
Armin Reininger	Senior Scientific & Medical Advisor	7.9yrs	データなし	0.0047% € 431.7k
Norbert Oppitz	Head of International	7.2yrs	データなし	0.012% € 1.1m
Sofiane Fahmy	Head of Europe	5.9yrs	データなし	0.0077% € 715.3k
Duane Barnes	Head of North America	3.9yrs	データなし	データなし
Mahmood Ladha	Head of Strategic Transformation Operations	no data	データなし	0.0018% € 168.6k
Christine Wesstrom	Head of Technical Operations	2.8yrs	データなし	0.0032% € 298.3k
Lydia Abad-Franch	Senior VP	1.9yrs	データなし	データなし

5.9yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: B6Eの経営陣は経験豊富で経験豊富です（平均在職期間は5.9年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Hans Wigzell	Chairman of Scientific Advisory Board	23.9yrs	SEK 158.00k	データなし
Helena Saxon	Director	13.7yrs	SEK 828.00k	0.0067% € 617.0k
Anders Ullman	Director	1.6yrs	SEK 463.00k	0.0010% € 92.6k
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	データなし	データなし
Ralf Pettersson	Member of Scientific Advisory Board	no data	データなし	データなし
Stefan Del Prato	Member of Scientific Advisory Board	no data	データなし	データなし
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	データなし	データなし
Annette Clancy	Independent Director	10.6yrs	SEK 770.00k	0.00099% € 91.7k
Staffan Schuberg	Independent Director	4.6yrs	SEK 827.00k	0.0021% € 192.7k
Filippa Stenberg	Director	3.6yrs	SEK 673.00k	0.00017% € 15.8k
David Meek	Chairman	no data	データなし	データなし
Katy Mazibuko	Employee Representative Director	1.9yrs	データなし	0.0013% € 117.7k

4.1yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: B6Eの取締役会は経験豊富であると考えられます ( 4.1年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/25 05:38
終値	2024/12/23 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Swedish Orphan Biovitrum AB (publ) 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。29

アナリスト	機関
Alexander Lindström	ABG Sundal Collier
Rosie Turner	Barclays
Brian Balchin	Barclays

Swedish Orphan Biovitrum マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

General Counsel & Head of Legal Affairs recently sold €2.4m worth of stock

CEO & President recently sold €2.5m worth of stock

Head of North America recently sold €3.3m worth of stock

CEO & President recently sold €2.6m worth of stock

Recent updates

Swedish Orphan Biovitrum AB (Publ) Elects David Meek as Member of the Board of Directors and Chair of the Board of Directors

Swedish Orphan Biovitrum AB (Publ) Announces Annette Clancy Has Informed the Nomination Committee That Will Not Be Available for Re-Election as Chair

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Third quarter 2024 earnings released: EPS: kr4.27 (vs kr0.30 in 3Q 2023)

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2024 Results on Mar 31, 2025

Swedish Orphan Biovitrum AB (publ) to Report Q2, 2025 Results on Jul 16, 2025

General Counsel & Head of Legal Affairs recently sold €2.4m worth of stock

Investor sentiment improves as stock rises 16%

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

CEO & President recently sold €2.5m worth of stock

Sobi Announces the Publication of Full Results from the Phase 3 XTEND- Kids Study in Thenew England Journal of Medicine Confirming the Safety and Efficacy Profile of Altuvoct

Second quarter 2024 earnings released: EPS: kr0.66 (vs kr0.71 in 2Q 2023)

Swedish Orphan Biovitrum AB (publ) Updates Earnings Guidance for the Year 2024

Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout

European Commission Grants Sobi® Marketing Authorisation for Altuvoct™ for Treatment of Haemophilia A

Head of North America recently sold €3.3m worth of stock

CEO & President recently sold €2.6m worth of stock

Swedish Orphan Biovitrum AB (publ) Elects Zlatko Rihter as New Board Member

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold €501k worth of stock

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Senior Scientific & Medical Advisor recently sold €1.4m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings released: EPS: kr0.30 (vs kr1.52 in 3Q 2022)

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings released: EPS: kr0.75 (vs kr0.87 in 2Q 2022)

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought €1.0m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021)

Insider recently sold €1.2m worth of stock

Head of Europe recently sold €1.4m worth of stock

CEO & President recently sold €2.2m worth of stock

Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021)

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released: EPS: kr1.52 (vs kr1.60 in 3Q 2021)

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa

Second quarter 2022 earnings released: EPS: kr0.87 (vs kr0.91 in 2Q 2021)

Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi

Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member

First quarter 2022 earnings released: EPS: kr1.84 (vs kr2.36 in 1Q 2021)

Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study

Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH)

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022

Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

マネジメント基準チェック /44